678TiP A phase I, first-in-human, dose escalation and expansion study of oral pan-RAF/MEK molecular glue NST-628 in subjects with solid tumors harboring RAS-MAPK pathway alterations. - Lemech, C.; Luke, J.J.; Falchook, G.S.; Mckean, M.; Kichenadasse, G.; Teng, C.; Vandross, A.L.; Salkeni, M.A.; Atkinson, V.G.; Liu, J.J.; Kennedy, A.M.; Clark, J.; et al. (Annals of Oncology, 2024)